Medtronic PLC $MDT Stock Holdings Decreased by Syntax Research Inc.

Syntax Research Inc. lessened its stake in Medtronic PLC (NYSE:MDT) by 87.5% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 803 shares of the medical technology company’s stock after selling 5,637 shares during the quarter. Syntax Research Inc.’s holdings in Medtronic were worth $63,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of MDT. Brighton Jones LLC raised its stake in Medtronic by 1,368.0% during the fourth quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock valued at $3,194,000 after buying an additional 37,265 shares in the last quarter. Sivia Capital Partners LLC grew its position in shares of Medtronic by 9.6% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock worth $380,000 after acquiring an additional 381 shares in the last quarter. Jump Financial LLC acquired a new position in shares of Medtronic in the 2nd quarter worth approximately $299,000. Main Street Financial Solutions LLC grew its position in shares of Medtronic by 28.9% in the 2nd quarter. Main Street Financial Solutions LLC now owns 14,356 shares of the medical technology company’s stock worth $1,251,000 after acquiring an additional 3,218 shares in the last quarter. Finally, HUB Investment Partners LLC increased its holdings in shares of Medtronic by 21.3% in the 2nd quarter. HUB Investment Partners LLC now owns 19,226 shares of the medical technology company’s stock valued at $1,676,000 after acquiring an additional 3,376 shares during the last quarter. Institutional investors own 82.06% of the company’s stock.

Medtronic Trading Up 0.7%

Shares of NYSE MDT opened at $92.87 on Friday. The company has a market cap of $118.87 billion, a price-to-earnings ratio of 22.87, a price-to-earnings-growth ratio of 2.16 and a beta of 0.56. Medtronic PLC has a 12-month low of $73.31 and a 12-month high of $106.33. The company has a current ratio of 2.13, a quick ratio of 1.62 and a debt-to-equity ratio of 0.52. The stock’s 50 day simple moving average is $86.52 and its 200 day simple moving average is $85.31.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.39 by $0.06. The business had revenue of $9.76 billion during the quarter, compared to analyst estimates of $9.55 billion. Medtronic had a return on equity of 14.89% and a net margin of 13.93%.The business’s revenue for the quarter was up 13.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.26 EPS. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Equities research analysts expect that Medtronic PLC will post 5.95 EPS for the current year.

Medtronic Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 16th. Stockholders of record on Friday, September 25th will be issued a dividend of $0.72 per share. The ex-dividend date of this dividend is Friday, September 25th. This represents a $2.88 annualized dividend and a dividend yield of 3.1%. Medtronic’s payout ratio is 70.94%.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic’s fiscal first-quarter results exceeded expectations, with adjusted EPS of $1.45 versus the $1.39 consensus and revenue of $9.76 billion versus $9.55 billion expected. Revenue increased 13.7% year over year, while management raised its fiscal 2027 outlook to approximately $5.94-$6.00 in EPS. Medtronic Begins Fiscal 2027 With a Beat-and-Raise
• Positive Sentiment: Analysts responded favorably to the earnings beat and raised guidance. RBC reaffirmed its Outperform rating with a $118 price target, while TD Cowen maintained a Buy rating; other firms also increased their targets. Medtronic Analysts Raise Their Forecasts
• Positive Sentiment: Management highlighted broad-based growth across major franchises and newer platforms, including robotics and ablation. Investors view this as evidence that Medtronic’s multiyear growth recovery may be gaining momentum. MDT Earnings Call Focuses on Broad Growth
• Positive Sentiment: A PERSIST addendum study is generating additional real-world evidence for Medtronic’s Inceptiv spinal cord stimulation system, potentially strengthening physician adoption and investor confidence. Medtronic’s PERSIST Study
• Positive Sentiment: Medtronic entered a strategic partnership with Cornerstone Robotics intended to expand global access to robot-assisted surgery, supporting its long-term robotics strategy. Cornerstone Robotics Partnership
• Negative Sentiment: Market strategists warned that Medtronic has become a crowded healthcare-sector trade. The recommendation included using options to bet on a decline, reflecting concern that excessive bullish positioning could limit further gains or trigger a pullback. Crowded Healthcare Stocks

Wall Street Analyst Weigh In

Several research firms recently issued reports on MDT. Royal Bank Of Canada reissued an “outperform” rating and set a $118.00 price target on shares of Medtronic in a research report on Wednesday. Needham & Company LLC lifted their price objective on shares of Medtronic from $101.00 to $114.00 and gave the stock a “buy” rating in a report on Thursday, August 27th. Weiss Ratings reiterated a “hold (c)” rating on shares of Medtronic in a research note on Tuesday, August 18th. Sanford C. Bernstein dropped their target price on shares of Medtronic from $112.00 to $97.00 and set an “outperform” rating on the stock in a report on Thursday, June 4th. Finally, TD Cowen raised their price target on shares of Medtronic from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Friday, August 28th. Nineteen analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $103.92.

Insider Activity

In other news, EVP Harry Kiil sold 4,189 shares of the company’s stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $80.44, for a total transaction of $336,963.16. Following the completion of the transaction, the executive vice president owned 37,227 shares in the company, valued at approximately $2,994,539.88. This represents a 10.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.27% of the company’s stock.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).